Compare SBSW & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBSW | CYTK |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.0B |
| IPO Year | N/A | 2004 |
| Metric | SBSW | CYTK |
|---|---|---|
| Price | $13.19 | $61.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | $6.90 | ★ $77.87 |
| AVG Volume (30 Days) | ★ 4.8M | 1.8M |
| Earning Date | 08-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,290,132,787.00 | $87,211,000.00 |
| Revenue This Year | $14.61 | $361.33 |
| Revenue Next Year | $15.74 | $65.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.11 | ★ 2609.26 |
| 52 Week Low | $3.05 | $29.31 |
| 52 Week High | $13.40 | $69.33 |
| Indicator | SBSW | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 46.45 |
| Support Level | $12.10 | $59.56 |
| Resistance Level | $12.81 | $67.26 |
| Average True Range (ATR) | 0.52 | 2.35 |
| MACD | 0.05 | -0.87 |
| Stochastic Oscillator | 66.67 | 23.49 |
Sibanye Stillwater Ltd is a South African mining and metals processing group with a diverse portfolio of operations, projects, and investments across five continents. The Group is also one of the foremost recyclers of PGM autocatalysts and has interests in mine tailings retreatment operations. It is a producer of platinum, palladium, and rhodium and is a top-tier gold producer. It also produces and refines iridium and ruthenium, nickel, chrome, copper, and cobalt. Its products are Gold, Nickel, Zinc, Chrome, PGMs, and other.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.